Cryptococcosis diagnosis and treatment: What do we know now

被引:146
作者
Perfect, John R. [1 ]
Bicanic, Tihana [2 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA
[2] Univ London, Inst Infect & Immun, London, England
关键词
Medical mycology; Management; Meningitis; Pathophysiology; HIGH-DOSE FLUCONAZOLE; COURSE AMPHOTERICIN-B; HIV-INFECTED PATIENTS; INTRACRANIAL-PRESSURE; ANTIFUNGAL THERAPIES; FUNGAL BURDEN; LATERAL FLOW; MENINGITIS; NEOFORMANS; AIDS;
D O I
10.1016/j.fgb.2014.10.003
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cryptococcosis has evolved into a major invasive fungal disease over the last century. Its primary epidemiology has been focused on three major outbreaks of disease that reflects both changing environmental exposures and growth of host risk factors. The molecular understandings of yeast pathobiology have been bolstered by identification of the yeast's dynamic genomic structures and functions. It is during these new insights into epidemiology and pathobiology that we have also improved our diagnosis of this infection with a new point-of-care, simple, cheap test which utilizes a lateral flow assay for antigen detection. With methods for effective identification of Cryptococcus in the host, the principles for management of this deadly infection include both use of old drugs and new insights into treatment strategies to improve outcome. In this review there are a series of recent insights, opinions, and facts which attempt to summarize our present knowledge base for this deadly fungal central nervous system infection with a particular emphasis on its diagnosis and management. (C) 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
引用
收藏
页码:49 / 54
页数:6
相关论文
共 64 条
  • [31] Survival Defects of Cryptococcus neoformans Mutants Exposed to Human Cerebrospinal Fluid Result in Attenuated Virulence in an Experimental Model of Meningitis
    Lee, Anthony
    Toffaletti, Dena L.
    Tenor, Jennifer
    Soderblom, Erik J.
    Thompson, J. Will
    Moseley, M. Arthur
    Price, Michael
    Perfect, John R.
    [J]. INFECTION AND IMMUNITY, 2010, 78 (10) : 4213 - 4225
  • [32] Treatment of Cryptococcal Meningitis in KwaZulu-Natal, South Africa
    Lightowler, Josephine V. J.
    Cooke, Graham S.
    Mutevedzi, Portia
    Lessells, Richard J.
    Newell, Marie-Louise
    Dedicoat, Martin
    [J]. PLOS ONE, 2010, 5 (01):
  • [33] Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days
    Livermore, Joanne
    Howard, Susan J.
    Sharp, Andrew D.
    Goodwin, Joanne
    Gregson, Lea
    Felton, Timothy
    Schwartz, Julie A.
    Walker, Catherine
    Moser, Bill
    Mueller, Werner
    Harrison, Thomas S.
    Perfect, John R.
    Hope, William W.
    [J]. MBIO, 2014, 5 (01):
  • [34] Dose Response Effect of High-Dose Fluconazole for HIV-Associated Cryptococcal Meningitis in Southwestern Uganda
    Longley, Nicky
    Muzoora, Conrad
    Taseera, Kabanda
    Mwesigye, James
    Rwebembera, Joselyne
    Chakera, Ali
    Wall, Emma
    Andia, Irene
    Jaffar, Shabbar
    Harrison, Thomas S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (12) : 1556 - 1561
  • [35] Cryptococcal immune reconstitution inflammatory syndrome
    Longley, Nicky
    Harrison, Thomas S.
    Jarvis, Joseph N.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2013, 26 (01) : 26 - 34
  • [36] Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries
    Loyse, Angela
    Thangaraj, Harry
    Easterbrook, Philippa
    Ford, Nathan
    Roy, Monika
    Chiller, Tom
    Govender, Nelesh
    Harrison, Thomas S.
    Bicanic, Tihana
    [J]. LANCET INFECTIOUS DISEASES, 2013, 13 (07) : 629 - 637
  • [37] Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS
    Mayanja-Kizza, H
    Oishi, K
    Mitarai, S
    Yamashita, H
    Nalongo, K
    Watanabe, K
    Izumi, T
    Ococi-Jungala
    Augustine, K
    Mugerwa, R
    Nagatake, T
    Matsumoto, K
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (06) : 1362 - 1366
  • [38] McKenney J, 2014, MMWR-MORBID MORTAL W, V63, P585
  • [39] Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/mL Who Start HIV Therapy in Resource-Limited Settings
    Meya, David B.
    Manabe, Yukari C.
    Castelnuovo, Barbara
    Cook, Bethany A.
    Elbireer, Ali M.
    Kambugu, Andrew
    Kamya, Moses R.
    Bohjanen, Paul R.
    Boulware, David R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (04) : 448 - 455
  • [40] Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis
    Muzoora, Conrad K.
    Kabanda, Taseera
    Ortu, Giuseppina
    Ssentamu, John
    Hearn, Pasco
    Mwesigye, James
    Longley, Nicky
    Jarvis, Joseph N.
    Jaffar, Shabbar
    Harrison, Thomas S.
    [J]. JOURNAL OF INFECTION, 2012, 64 (01) : 76 - 81